Ace Vision Group Raises $29.4M to Advance Presbyopia Laser

Ace Vision Group (AVG) has announced the successful closing of a $29.4 million Series B financing round. The capital will be used to advance the development of the company’s proprietary Gen II VisioLite Ophthalmic Laser, which delivers the minimally invasive Laser Scleral Microporation (LSM) procedure. LSM is designed to address the loss of Dynamic Range of Focus caused by presbyopia.

Strategic Milestone to Enable Clinical Trials and Regulatory Filing

“This Series B funding marks a critical inflection point for our company,” stated AnnMarie Hipsley, PhD, Founder and CEO of Ace Vision Group, in the company’s news release.

“It enables us to finalize the research and design of our commercial system and positions us to initiate clinical trials both in the US and internationally. We remain on track to submit our 510(k) application in 2026.”

LSM Technology Targets Root Cause of Presbyopia

Ace Vision Group’s patented LSM technology is positioned to become the first laser-based, in-office therapeutic designed to treat progressive presbyopia. By reducing age-related ocular rigidity, the approach aims to restore functional near vision.

In a recent pilot study using the Gen I device, AVG reported encouraging results. A majority of patients no longer required reading glasses after undergoing the LSM procedure.

Addressing a Growing Market Demand for In-Office Solutions

“There is a clear and growing demand for in-office, ultra-minimally invasive solutions that address the root cause of presbyopia while preserving patient convenience and clinical efficiency," said Dr. Hipsley.

“AVG’s technology aligns directly with this unmet need, offering a scalable, procedure-based model that integrates seamlessly into ophthalmic practices. This level of market relatability, combined with strong clinical interest and favorable economics, positions us for broad adoption and long-term value creation.”